Navigation Links
Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone

VIENNA, December 19, 2011 /PRNewswire/ --

APEIRON Biologics AG (Apeiron) announced today that GlaxoSmithKline (GSK), exclusive, worldwide licensee for Apeiron's new investigational recombinant human Angiotensin Converting Enzyme 2 (rhACE2, name: GSK2586881, formerly APN01), has initiated a phase IIa study in patients suffering from Acute Lung Injury.

Apeiron today announced the initiation of a phase IIa clinical study of rhACE2, in patients with Acute Lung Injury (ALI). The study, of which Apeiron's licensee GSK is sponsor, will include subjects with a positive diagnosis of ALI, and will be conducted in the intensive care units of multiple hospitals throughout the United States and Canada.

ALI is an acute, severe injury to the lungs associated with a variety of underlying conditions, such as sepsis, aspiration of acidic gastric contents, trauma, postoperative complications, acute pancreatitis, and pneumonia. According to recent studies, it annually affects hundreds of thousands of individuals worldwide. There are currently no pharmaceutical therapies available to treat this life-threatening condition. The most severe form of ALI, the Acute Respiratory Distress Syndrome (ARDS) has a mortality rate of over 20-40%. The efficacy of GSK2586881 has been tested in several preclinical animal models of ALI/ARDS. A phase I study in healthy volunteers also investigated the safety, tolerability and pharmacology profile of this investigational medicine.  In January 2010, GSK acquired an exclusive, worldwide license to further develop and commercialize GSK2586881 in a deal worth up to EUR 230 Mio, subject to reaching future development milestones in multiple indications.

Hans Loibner, CEO of Apeiron stated: "We are excited to see our innovative biologic APN01, after only 6 years in development, now being tested by our licensee GSK in a multicentric phase II study in ALI patients. The study is designed to provide important information regarding the safety and pharmacologic profile of this recombinant enzyme in this severely diseased patient population, as well as first insights into its clinical efficacy. This event is an important milestone for our company and validates our efforts to clinically advance novel therapies for severe conditions where there is significant unmet medical need."

About Apeiron (as of December 2011):

Apeiron is a privately financed biotech based in Vienna, Austria. Apeiron focuses on biological and immunological treatments against cancer and related conditions. Apeiron's project portfolio consists of five projects under clinical evaluation, and several preclinical projects. Clinical projects include the immunocytokine hu14.18-IL2 (APN301) that recently entered into phase II (for certain neuroblastoma patients) and is also being clinically tested against melanoma.

A liposomal formulation of recombinant human Superoxide Dismutase (APN201) is also in the clinical stage of development to prevent or treat skin damage due to radiation treatment in cancer. Recombinant human Angiotensin Converting Enzyme 2 (GSK2586881, formerly APN01), was licensed to GlaxoSmithKline in early 2010. Apeiron presently employs 25 people and has been in operation since 2006.

Contact Apeiron:
Dr. Hans Loibner, CEO    
Campus-Vienna-Biocenter 5
1030 Vienna, Austria
T +43(0)1-865-6577

Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43(0)1-505-70-44

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management
2. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
3. Garage Start-ups Now Possible in Life Sciences Industry
4. Angioslide Named One of Israels Top Ten Most Promising Startups of 2011
5. False starts can sneak by in womens sprinting
6. Good Start Genetics™ Announces Validation Results for its Next-Generation DNA Sequencing Platform for Genetic Disorder Carrier Screening
7. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
8. Midwest Health Care Startups Raise $315 Million in First Half of 2011
9. Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects
10. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
11. BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), ... MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing ... AMA members have embraced this type of racing and several new model aviation pilots ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies would ... named to Deloitte's 2015 Technology Fast 500 list of the fastest growing companies ... FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by as ...
Breaking Biology Technology:
(Date:10/26/2015)... ALTO, Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern ... Alliance , today announced the launch of its latest ... first unified platform enabling organizations to use standards-based authentication ... The Nok Nok S3 Authentication Suite is ideal for ...
(Date:10/23/2015)... Research and Markets ( ) has announced the ... 2015-2019" report to their offering. ... recognition biometrics market to grow at a CAGR of ... --> The report, Global Voice Recognition Biometrics ... market analysis with inputs from industry experts. The report ...
(Date:10/22/2015)... Oct. 22, 2015  Aware, Inc. (NASDAQ: AWRE ), a ... for its third quarter ended September 30, 2015.  ... of 2015 was $4.0 million, a decrease of 33% compared to ... the third quarter of 2015 was $2.2 million, or $0.10 per ... share, in the same period a year ago.  ...
Breaking Biology News(10 mins):